Characterization of lean patients with nonalcoholic fatty liver disease: Potential role of high hemoglobin levels

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 3, 2014, Pages 341-346

  Akyuz, Umit ^a,b   Yesil, Atakan ^a   Yilmaz, Yusuf ^c  

^a YEDITEPE UNIVERSITY   (Turkey)

^b Fatih Sultan Mehmet Education and Research Hospital   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Body mass index; Fibrosis; Hemoglobin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; FERRITIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIPID STORAGE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BIOPSY; BODY WEIGHT; COMPLICATION; ECHOGRAPHY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; BIOPSY; BODY MASS INDEX; FEMALE; HEMOGLOBINS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OVERWEIGHT; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THINNESS;

EID: 84922711376     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.983160     Document Type: Article

References (28)

1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-50.
2. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-18.
3. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
4. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42: 320-30.
5. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014;164:312-22.
6. Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011;2011:592404.
7. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
8. Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AO, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012;42:411-18.
9. Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-alcoholic fatty liver disease (NAFLD) in obesity. J Clin Diagn Res 2014;8:62-6.
10. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496-500.
11. Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin North Am 2014;98:55-72.
12. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
13. Vos B, Moreno C, Nagy N, Féry F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74:389-94.
14. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319-27.
15. Dela Cruz AC, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, et al. Characteristics and longterm prognosis of lean patients with nonalcoholic fatty liver disease [abstract 379]. DDW 2014, Chicago, IL, USA.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
18. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825-32.
19. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009;58:1706-7.
20. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012;56:241-7.
21. Jiang Y, Zeng J, Chen B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J Gastroenterol Hepatol 2014;29:1508-14.
22. Bai CH, Wu MS, Owaga E, Cheng SY, Pan WH, Chang JS. Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults. Chin J Physiol 2014;57:5.
23. Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One 2011;6:e24363.
24. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102:1251-8.
25. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:720-9.
26. Huang CH, Chang CC, Kuo CL, Huang CS, Chiu TW, Lin CS, et al. Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. PLoS One 2014;9:e104495.
27. Yoneda M, Thomas E, Sumida Y, Imajo K, Eguchi Y, Hyogo H, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with nonalcoholic fatty liver disease: proceed with caution. Hepatol Res 2014; Epub ahead of print.
28. Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014;39:532-9.